exRNAdisease

General Information

Database ID:

exR0087719

RNA Name:

hsa-miR-129-5p

RNA Type:

miRNA

Chromosome:

chr7

Starnd:

Coordinate:

Start Site(bp):

128207876

End Site(bp):

128207896

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
TNRC6B	chr22	40044817	40335808	+
KRIT1	chr7	92198969	92246166	-
SLC7A2	chr8	17497088	17570573	+
TRIM71	chr3	32817997	32897824	+
SHCBP1	chr16	46578591	46621379	-
NEDD4	chr15	55826922	55993746	-
ZNF605	chr12	132918306	132956306	-
DDX18	chr2	117814691	117832377	+
CPSF7	chr11	61402641	61430031	-
RAD1	chr5	34905260	34918989	-
UBN2	chr7	139230356	139308236	+
DEGS1	chr1	224175756	224193441	+
SEC62	chr3	169966635	169998373	+
CRK	chr17	1420689	1463162	-
SLC35E1	chr19	16549831	16572415	-
TRIM14	chr9	98069275	98119222	-
ALDH5A1	chr6	24494867	24537207	+
UFL1	chr6	96521595	96555276	+
DUSP14	chr17	37489891	37513501	+
WSB1	chr17	27294076	27315926	+
DNAJC24	chr11	31369840	31432835	+
CHURC1	chr14	64914361	64944591	+
MLEC	chr12	120687149	120701859	+
CAMTA1	chr1	6785454	7769706	+
THUMPD1	chr16	20702816	20742084	-
EIF4A1	chr17	7572706	7579006	+
ACER3	chr11	76860867	77026797	+
TTPAL	chr20	44475874	44494603	+
PDS5A	chr4	39822863	39977956	-
FBXW7	chr4	152320544	152536092	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000943	chr19	47421744	47440665	+
hsa_circ_0001168	chr20	47691321	47707559	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC004069.1	chr4	105137280	105140619	-
AC097634.1	chr3	71584943	71587409	+
AL049795.2	chr1	32170733	32176568	+
FGD5-AS1	chr3	14920347	14948424	-
MALAT1	chr11	65497688	65506516	+
NEAT1	chr11	65422774	65445540	+
NUTM2A-AS1	chr10	87201647	87342612	-
OIP5-AS1	chr15	41283990	41309737	+
TBC1D3P1-DHX40P1	chr17	59962363	60018975	-
TUG1	chr22	30969245	30979395	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.